Premium
High‐dose therapy and autologous stem cell transplantation for children with HIV‐associated non‐Hodgkin lymphoma
Author(s) -
Fluri Simon,
Ammann Roland,
Lüthy Annette Ridolfi,
Hirt Andreas,
Aebi Christoph,
Duppenthaler Andrea,
Leibundgut Kurt
Publication year - 2007
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.20900
Subject(s) - medicine , lymphoma , salvage therapy , rituximab , autologous stem cell transplantation , oncology , radiation therapy , transplantation , stem cell , refractory (planetary science) , human immunodeficiency virus (hiv) , chemotherapy , surgery , immunology , physics , biology , astrobiology , genetics
Abstract In contrast to adults, autologous stem cell transplantation (ASCT) as part of the salvage strategy after high‐dose chemo/radiotherapy in human immunodeficiency virus (HIV) related Non‐Hodgkin lymphoma (NHL) is not yet established for children. We report on a 13‐year patient with congenital HIV infection and refractory Burkitt lymphoma, who was successfully treated by high‐dose therapy (HDT) including rituximab followed by ASCT. After 26 months follow‐up the patient remains in complete remission and his HIV parameters have normalized with continued highly active antiretroviral therapy (HAART). HIV infection may no longer exclude children from ASCT as part of salvage therapy. Pediatr Blood Cancer 2007;49:984–987. © 2006 Wiley‐Liss, Inc.